Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2006

View Archived Issues

New data on malaria vaccines reported at tropical medicine meeting

Intravenous artesunate investigated in malaria

Pharmacological profile of AstraZeneca's novel P2X7 receptor agonist reported

Novel camptothecin prodrug analogue developed at Chugai

Mochida's novel PARP-1 inhibitor could be a candidate for the treatment of ischemic disorders

Oral bioavailability results support advancement of CK-1827452 into phase II

IND granted for Erwinase

Semafore receives grant to support phase I study of SF-1126

German approval for Eligard six-month formulation

Merck & Co. announces trademark Janumet

Peptech acquires cancer-related antibodies from Scancell

Cell Therapeutics updates pipeline progress

Gene therapy for alpha1-antitrypsin deficiency safe in humans

GCAN-101 preclinical, clinical results show anticancer activity

Rituximab studied in autoimmune diseases

Preclinical data support enhancement of TGF-beta signaling as a treatment for Alzheimer's disease

Novel mGluR1 antagonist developed at Astellas

Recent Kyowa Hakko patent imparts novel p38 MAPK inhibitors

Clera prepares and tests novel dopamine D2 receptor ligands

Spectrum reviews Q3 developments

Nexavar phase III study in melanoma fails to meet primary PFS endpoint

MPI studies with regadenoson comparable to MPI studies with Adenoscan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...